Imaging of nonprostate cancers using PSMA-targeted radiotracers

Rationale, current state of the field, and a call to arms

A. Salas Fragomeni Roberto, Tali Amir, Sara Sheikhbahaei, Susan Harvey, Mehrbod Som Som Javadi, Lilja Solnes, Ana Ponce Kiess, Mohamad E Allaf, Martin Gilbert Pomper, Michael Gorin, Steven Rowe

Research output: Contribution to journalArticle

Abstract

Prostate-specific membrane antigen (PSMA) is a type II transmem-brane glycoprotein that is highly overexpressed on prostate cancer epithelial cells and for which there is a growing body of literature examining the role of small-molecule and antibody radiotracers targeted against this protein for prostate cancer detection and therapy. Despite its name, PSMA is also expressed, to varying degrees, in the neovasculature of a wide variety of nonprostate cancers; indeed, the pathology literature is replete with promising immunohistochemistry findings. Several groups have begun to correlate those pathology-level results with in vivo imaging and therapy in nonprostate cancers using the same PSMA-targeted agents that have been so successful in prostate cancer. The potential to leverage radiotracers targeted to PSMA beyond prostate cancer is a promising approach for many cancers, and PSMA-targeted agents may be able to supplement or fill gaps left by other agents. However, to date, most of the reported findings with PSMA-targeted radiotracers in nonprostate malignancies have been in case reports and small case series, and the field must adopt a more thorough approach to the design and execution of larger prospective trials to realize the potential of these promising agents outside prostate cancer.

Original languageEnglish (US)
Pages (from-to)871-877
Number of pages7
JournalJournal of Nuclear Medicine
Volume59
Issue number6
DOIs
StatePublished - Jun 1 2018

Fingerprint

Prostatic Neoplasms
Pathology
Neoplasms
Names
human glutamate carboxypeptidase II
Glycoproteins
Epithelial Cells
Immunohistochemistry
Antibodies
Therapeutics
Proteins

Keywords

  • Breast cancer
  • Lung cancer
  • PET
  • PSMA
  • Renal cell carcinoma

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Imaging of nonprostate cancers using PSMA-targeted radiotracers : Rationale, current state of the field, and a call to arms. / Roberto, A. Salas Fragomeni; Amir, Tali; Sheikhbahaei, Sara; Harvey, Susan; Javadi, Mehrbod Som Som; Solnes, Lilja; Kiess, Ana Ponce; Allaf, Mohamad E; Pomper, Martin Gilbert; Gorin, Michael; Rowe, Steven.

In: Journal of Nuclear Medicine, Vol. 59, No. 6, 01.06.2018, p. 871-877.

Research output: Contribution to journalArticle

@article{88a774b25c2c4329bee1c9107e916e10,
title = "Imaging of nonprostate cancers using PSMA-targeted radiotracers: Rationale, current state of the field, and a call to arms",
abstract = "Prostate-specific membrane antigen (PSMA) is a type II transmem-brane glycoprotein that is highly overexpressed on prostate cancer epithelial cells and for which there is a growing body of literature examining the role of small-molecule and antibody radiotracers targeted against this protein for prostate cancer detection and therapy. Despite its name, PSMA is also expressed, to varying degrees, in the neovasculature of a wide variety of nonprostate cancers; indeed, the pathology literature is replete with promising immunohistochemistry findings. Several groups have begun to correlate those pathology-level results with in vivo imaging and therapy in nonprostate cancers using the same PSMA-targeted agents that have been so successful in prostate cancer. The potential to leverage radiotracers targeted to PSMA beyond prostate cancer is a promising approach for many cancers, and PSMA-targeted agents may be able to supplement or fill gaps left by other agents. However, to date, most of the reported findings with PSMA-targeted radiotracers in nonprostate malignancies have been in case reports and small case series, and the field must adopt a more thorough approach to the design and execution of larger prospective trials to realize the potential of these promising agents outside prostate cancer.",
keywords = "Breast cancer, Lung cancer, PET, PSMA, Renal cell carcinoma",
author = "Roberto, {A. Salas Fragomeni} and Tali Amir and Sara Sheikhbahaei and Susan Harvey and Javadi, {Mehrbod Som Som} and Lilja Solnes and Kiess, {Ana Ponce} and Allaf, {Mohamad E} and Pomper, {Martin Gilbert} and Michael Gorin and Steven Rowe",
year = "2018",
month = "6",
day = "1",
doi = "10.2967/jnumed.117.203570",
language = "English (US)",
volume = "59",
pages = "871--877",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "6",

}

TY - JOUR

T1 - Imaging of nonprostate cancers using PSMA-targeted radiotracers

T2 - Rationale, current state of the field, and a call to arms

AU - Roberto, A. Salas Fragomeni

AU - Amir, Tali

AU - Sheikhbahaei, Sara

AU - Harvey, Susan

AU - Javadi, Mehrbod Som Som

AU - Solnes, Lilja

AU - Kiess, Ana Ponce

AU - Allaf, Mohamad E

AU - Pomper, Martin Gilbert

AU - Gorin, Michael

AU - Rowe, Steven

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Prostate-specific membrane antigen (PSMA) is a type II transmem-brane glycoprotein that is highly overexpressed on prostate cancer epithelial cells and for which there is a growing body of literature examining the role of small-molecule and antibody radiotracers targeted against this protein for prostate cancer detection and therapy. Despite its name, PSMA is also expressed, to varying degrees, in the neovasculature of a wide variety of nonprostate cancers; indeed, the pathology literature is replete with promising immunohistochemistry findings. Several groups have begun to correlate those pathology-level results with in vivo imaging and therapy in nonprostate cancers using the same PSMA-targeted agents that have been so successful in prostate cancer. The potential to leverage radiotracers targeted to PSMA beyond prostate cancer is a promising approach for many cancers, and PSMA-targeted agents may be able to supplement or fill gaps left by other agents. However, to date, most of the reported findings with PSMA-targeted radiotracers in nonprostate malignancies have been in case reports and small case series, and the field must adopt a more thorough approach to the design and execution of larger prospective trials to realize the potential of these promising agents outside prostate cancer.

AB - Prostate-specific membrane antigen (PSMA) is a type II transmem-brane glycoprotein that is highly overexpressed on prostate cancer epithelial cells and for which there is a growing body of literature examining the role of small-molecule and antibody radiotracers targeted against this protein for prostate cancer detection and therapy. Despite its name, PSMA is also expressed, to varying degrees, in the neovasculature of a wide variety of nonprostate cancers; indeed, the pathology literature is replete with promising immunohistochemistry findings. Several groups have begun to correlate those pathology-level results with in vivo imaging and therapy in nonprostate cancers using the same PSMA-targeted agents that have been so successful in prostate cancer. The potential to leverage radiotracers targeted to PSMA beyond prostate cancer is a promising approach for many cancers, and PSMA-targeted agents may be able to supplement or fill gaps left by other agents. However, to date, most of the reported findings with PSMA-targeted radiotracers in nonprostate malignancies have been in case reports and small case series, and the field must adopt a more thorough approach to the design and execution of larger prospective trials to realize the potential of these promising agents outside prostate cancer.

KW - Breast cancer

KW - Lung cancer

KW - PET

KW - PSMA

KW - Renal cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=85048184545&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048184545&partnerID=8YFLogxK

U2 - 10.2967/jnumed.117.203570

DO - 10.2967/jnumed.117.203570

M3 - Article

VL - 59

SP - 871

EP - 877

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 6

ER -